TLR3 and neoplasm: While mice treated with either CD40 or TLR3 agonist responded with modest tumor growth delay and increased survival, combined TLR3/CD40 stimulation resulted in superior tumor control and survival in all three tumor models (Fig. 4a and Supplementary Fig. 8).